Deal Spotlight
September 20, 2026
Exciva raises EUR51M in Series B with EQT Life Sciences and GIMV
EUR51M
round size
seed
stage
The Series B round closed on September 15, 2026, with participation from EQT Life Sciences and GIMV. To date, the company has raised EUR118.2M across four funding rounds.
Exciva develops innovative therapeutic solutions for neurological diseases, focusing on epilepsy and other neurological disorders. The company is based in Germany and operates in Healthcare & Life Sciences at the seed stage. It was founded by Mark Altmeyer.
Brouky tracks 192 Healthcare & Life Sciences deals in Germany over the past twelve months, with a median investment amount of EUR10M.
Related insights
- Cross-Country AnalysisEnergy, Environment & Mobility funding share rose 2.2pp, while Commerce & Marketing fell 3.7pp from pre-seed to seed
- Deal SpotlightHiDream.ai raises EUR195M Series C+ backed by Fortune
- Cross-Country AnalysisFinance & Blockchain seed funding share declines 5.9pp, matched by Industry & Hardware’s 5.9pp gain from 2021 to 2024
- Cross-Country AnalysisHealthcare’s 2pp seed funding drop contrasts with Energy’s 4.3pp gain in France and Spain
Explore the full dataset
Brouky tracks 36,000+ investors and 100,000+ investments across 84,000+startups. Search by country, stage, and sector.